Gross Profit Comparison: BioMarin Pharmaceutical Inc. and Travere Therapeutics, Inc. Trends

BioMarin vs. Travere: A Decade of Profit Trends

__timestampBioMarin Pharmaceutical Inc.Travere Therapeutics, Inc.
Wednesday, January 1, 201462127600027632226
Thursday, January 1, 201573788700097707000
Friday, January 1, 2016907234000129037000
Sunday, January 1, 20171071860000151332000
Monday, January 1, 20181175948000158719000
Tuesday, January 1, 20191344582000170104000
Wednesday, January 1, 20201336183000192195000
Friday, January 1, 20211375760000220706000
Saturday, January 1, 20221612370000204426000
Sunday, January 1, 20231842161000133788000
Monday, January 1, 20242273680000
Loading chart...

Unleashing the power of data

A Tale of Two Biotech Giants: BioMarin vs. Travere

In the dynamic world of biotechnology, financial performance is a key indicator of a company's health and potential. Over the past decade, BioMarin Pharmaceutical Inc. and Travere Therapeutics, Inc. have showcased contrasting trajectories in their gross profit trends. From 2014 to 2023, BioMarin's gross profit surged by nearly 200%, reflecting its robust growth and market adaptability. In contrast, Travere's growth, while positive, was more modest, with an increase of approximately 380% over the same period. This disparity highlights BioMarin's dominant position in the market, consistently outperforming Travere by a significant margin. The year 2023 marked a peak for BioMarin, achieving its highest gross profit, while Travere experienced a slight dip. These trends underscore the competitive landscape of the biotech industry, where innovation and strategic investments drive financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025